January 25th 2012 | Biologics, Patient Stories, Psoriasis Cure Now, Psoriasis Research, Public policy issues, psoriatic arthritis | 4 Comments
Before 2011 becomes a distant memory, Psoriasis Cure Now felt it would be useful to highlight what we believe were the top psoriasis and psoriatic arthritis stories of 2011. The year included bad news about a promising treatment from Abbott, as well as a psoriasis sub-plot to one of the more ridiculous media sensations
READ THE FULL POST
February 16th 2011 | Get involved, Psoriasis Cure Now, Psoriasis Research, Public policy issues | 2 Comments
The US Government, through the National Institutes of Health (NIH), maintained in 2010 its record level of research funding for psoriasis and psoriatic arthritis. The total was $16 million, as it was in 2009. As recently as 2005 the total was just $5 million.
Progress!
Read more about research funding for psoriasis and psoriatic arthritis.
January 19th 2011 | Biologics, Psoriasis Research, Treatment | 0 Comments
Even treatments that are already approved by the U.S. Food and Drug Administration (FDA) are frequently tested further in clinical trials under close medical supervision. Such trials typically offer free meds and thorough medical screening – a great deal for patients. Check out our full report on psoriasis research studies for FDA-approved treatments.
With more
READ THE FULL POST
January 15th 2011 | Biologics, Psoriasis Research, Side-effects of treatment | 11 Comments
Abbott today announced in a securities filing that it has withdrawn its application with the U.S. Food and Drug Administration (FDA) and European regulators to market its much-anticipated, experimental psoriasis treatment briakinumab (ABT-874, Ozespa). The biologic, like Centocor Ortho Biotech’s Stelara (ustekinumab), targets two internal proteins linked to inflammation, IL-12 and IL-23. Briakinumab
READ THE FULL POST
November 1st 2010 | Psoriasis Research, Treatment, Triggers/environment | 2 Comments
A small study in Iceland found that tonsillectomy in those who tend to get psoriasis flares after strep throat infections produced reductions in psoriasis symptoms for most patients for the two-year duration of the study. As reported by Skin & Allergy News:
Tonsillectomy has beneficial clinical and immunologic effects on chronic plaque psoriasis in patients
READ THE FULL POST
October 31st 2010 | Psoriasis Research | 1 Comment
Amgen, one of the companies behind the leading biologic for psoriasis, Enbrel (etanercept), has at least two experimental treatments under development for moderate to severe psoriasis. It recently reported results from a Phase One trial of AMG 827, and is also developing AMG 714. Each would offer a novel approach to psoriasis treatment.
It’s
READ THE FULL POST
October 19th 2010 | Psoriasis Research | 0 Comments
Tasocitinib is an immune-suppressing medication being tested by pharmaceutical giant Pfizer for psoriasis and other diseases. It is a new type of drug called a Janus Kinase (JAK) inhibitor, and it is at least a couple years away from reaching market (it might actually reach market for rheumatoid arthritis [RA] first).
In a mid-stage, Phase
READ THE FULL POST
October 11th 2010 | Biologics, Psoriasis Research, Side-effects of treatment, Treatment | 10 Comments
[UPDATE 1/14/2011: Abbott today announced that it has withdrawn its application with the U.S. FDA to market briakinumab (ABT-874, Ozespa). Our full analysis of Abbott's pulling its briakinumab application is here. Our original, unedited post concerning the Phase Three trials is below.]
You know that buzz about Centocor Ortho Biotech’s biologic Stelara (ustekinumab),
READ THE FULL POST
October 7th 2010 | Biologics, Psoriasis Research, Treatment | 0 Comments
New data on Stelara (ustekinumab) has been presented at a European scientific meeting, and it shows Stelara performing well for most patients in the clinical trial, even after 2 years and 10 months of use. The company’s press release is here.
Some background on the study the data came from: Patients who weighed less
READ THE FULL POST
September 20th 2010 | Get involved, Psoriasis Cure Now, Psoriasis Research, Public policy issues, psoriatic arthritis | 0 Comments
With World Psoriasis Day coming on October 29, 2010, Psoriasis Cure Now has launched the World Psoriasis Day Challenge, to nudge the day toward focusing on increasing research funding worldwide for psoriasis and psoriatic arthritis. Check it out and let us know what you think! Comments are open below….
